Banner
HomeFocus → Regulatory Dead Zone May Be Holding Up Copycat Insulin

Regulatory Dead Zone May Be Holding Up Copycat Insulin Print E-mail
Written by Andrew Dunn | Healthcare Dive   
Monday, 21 January 2019 00:00
 
The insulin market has increasingly attracted scrutiny from politicians, regulators and patient groups, as prices ramp higher for the hormone that millions of diabetics depend on to stay alive. Food and Drug Administration head Scott Gottlieb has advocated for greater competition in the pharmaceutical industry as a means of bringing down drug costs. But, for insulin, changing legal rules have effectively created a "regulatory dead zone," hindering generic drugmakers filing applications for copycat versions of the biologic drug. 
 

Last Updated on Tuesday, 22 January 2019 18:16
 


Banner
Website design, development, and hosting provided by
Netphiles